Regulatory Reform in China: Implications for Global Biopharmaceutical Companies

June 15, 2016
David Deere
Volume 2016 ebook, Issue 1
Page Number: 22–28

New drug approval policies promote industry growth and injectable contract manufacturing opportunities in China.

New drug approval policies promote industry growth and injectable contract manufacturing opportunities in China. To compete in this resource-intensive manufacturing process that requires large volume capacity and a technically trained labor force, it is logical pharmaceutical companies will turn to contract manufacturing in China to meet strategic sourcing requirements.

Download the

.